How an Unproven Alzheimer’s Drug Got Approved
Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab.
View original article
Contributor: Pam Belluck, Sheila Kaplan and Rebecca Robbins
